LA
Lab #65
No description available
Team
Project Score
Powered by MIRAUpdated Sep 11, 2026
Technology Readiness Level
Technology Readiness Level
PRE-TRL
TRL 1
TRL 2
Project Progress
All updates
All categories
Timeline
Loading...
No description available
Therapeutic Relevance
Both KISS1R and OX2R programmes target well-validated, biologically relevant GPCR mechanisms. KISS1R agonism for IHH/fertility is clinically de-risked by MVT-602 and TAK-683 precedents. OX2R agonism was clinically validated by FDA approval of ORZEYFUL (oveporexton) in August 2026 for narcolepsy type 1, confirming the mechanism's therapeutic relevance. The proposed mechanisms are scientifically plausible and grounded in known biology (Class A GPCR signaling, Ca-flux readouts, established reference agonists KP-10 and orexin-B). The pulsatile dosing strategy for KISS1R to avoid tachyphylaxis and the intranasal peptide + hepatic-safety differentiation for OX2R show thoughtful mechanistic reasoning. Score is 4 rather than 5 because no proprietary functional data yet exists — Round-1 EC50/Emax results are still pending (~15 business days out), so the mechanistic hypothesis remains computationally supported but experimentally unconfirmed for PeptAI's specific compounds. Additionally, OX2R's ADHD indication via orexin hypofunction is more speculative than the narcolepsy validation.
Therapeutic Optionality
The project demonstrates strong therapeutic optionality across multiple dimensions. Two distinct GPCR targets (KISS1R and OX2R) are being pursued in parallel, each with multiple indication possibilities: KISS1R spans IHH and broader fertility applications, while OX2R covers narcolepsy type 1, ADHD, and potentially other wake/arousal disorders. The modality itself (peptide agonists) offers flexibility — the OX2R programme explicitly plans intranasal delivery as a differentiation strategy, and the platform approach (computational design → predict → wet-lab → recalibrate loop) is generalizable to other Class A GPCRs. The shots-on-goal strategy with ~100-peptide libraries and the DeorphaNN agonism predictor further expand optionality. Score is 4 rather than 5 because the platform's generalizability beyond these two targets is asserted but not yet demonstrated, and the de novo library (C3/C4) that would represent the broadest optionality has not yet been generated.
Intellectual Property
The IP picture is mixed at this stage. On the positive side, the de novo novel-IP arm (C3/C4 series, RFdiffusion/BoltzGen-seeded) is explicitly designed to have no KP-10 scaffold dependency and no prior art overlap, representing the strongest potential IP position. The OX2R peptide agonist approach occupies genuine white space — no peptide OX2R agonist exists in the clinic. However, significant IP risks remain unresolved: (1) C1-01 has acknowledged prior art overlap with Takeda (WO 2006/001499, Asami 2012, Takeda continuations) and has been reframed as a positive control rather than a novel lead; (2) FTO analysis via Undermind on C1-01/C1-02/C1-10 is still pending (M10); (3) the de novo C3/C4 library that would provide the strongest novel IP has not yet been generated, meaning the current wet-lab candidates (C1-01, C1-02) carry known prior art risk; (4) ADHD white space for OX2R is contested by Alkermes ALKS-7290. The concept is novel enough for patenting in principle (especially the de novo designs and stabilized peptide variants like OX2R-004-S1), but the IP position cannot be confirmed until FTO clears and de novo compounds are actually designed and validated.